Best Semaglutide Providers in 2026 — Ranked & Reviewed
Looking for a trusted semaglutide provider? We independently scored every major telehealth clinic offering compounded and brand-name semaglutide in 2026. Each provider is evaluated on pricing transparency, clinical oversight, shipping, and user experience — so you can find a legitimate, affordable option without falling for sketchy ads.
Lowest verified price: $25/mo335 providers compared
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
335 semaglutide providers compared · independently scored against our six-factor methodology.
Compare the top providers at a glance
Logos, our editorial rating, price, medications, and coverage — the fastest way to narrow the list.
- ★ Editor's Pick
mainstream telehealth GLP-1 access
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide lab-monitored compounded GLP-1 with mandatory video visit
From /mo$112Flat at every doseCoverage39 statesMedicationsSemaglutideTirzepatide- Nationwide Coverage
compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide
From /mo$129Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide mainstream telehealth GLP-1 access
From /mo$99Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide- Transparent Pricing
shoppers wanting physician-led, pharmacy-transparent compounded GLP-1 with brand-name options
From /mo$179Coverage50 statesMedicationsSemaglutideTirzepatide - Best Budget
budget-conscious shoppers
From /mo$93CoverageCheck intakeMedicationsSemaglutideTirzepatide compounded semaglutide and tirzepatide at a flat monthly price
From /mo$119Flat at every doseCoverageCheck intakeMedicationsSemaglutideTirzepatidemainstream telehealth GLP-1 access
From /mo$149CoverageCheck intakeMedicationsSemaglutideTirzepatideOrforglipron
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick mainstream telehealth GLP-1 access | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
 lab-monitored compounded GLP-1 with mandatory video visit | $112 Flat pricing | SemaglutideTirzepatide | 39 states | Visit → | |
Nationwide Coverage compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide | $129 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
 mainstream telehealth GLP-1 access | $99 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
Transparent Pricing shoppers wanting physician-led, pharmacy-transparent compounded GLP-1 with brand-name options | $179 | SemaglutideTirzepatide | 50 states | Visit → | |
Best Budget budget-conscious shoppers | $93 | SemaglutideTirzepatide | Check intake | Visit → | |
 compounded semaglutide and tirzepatide at a flat monthly price | $119 Flat pricing | SemaglutideTirzepatide | Check intake | Visit → | |
 mainstream telehealth GLP-1 access | $149 | SemaglutideTirzepatideOrforglipron | Check intake | Visit → |
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
Detailed Reviews
Found
Verified partnerBest for: mainstream telehealth GLP-1 access
Personalized weight care platform with a self-pay membership model plus medication costs.
Score Breakdown
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
Enhance MD
Verified partnerBest for: lab-monitored compounded GLP-1 with mandatory video visit
Enhance MD pairs compounded semaglutide and tirzepatide with mandatory baseline metabolic labs at Quest Diagnostics and a synchronous video visit with a board-certified clinician — a more rigorous onboarding than the async-only compounded GLP-1 model most telehealth providers use. Three tiers (Core semaglutide, Advanced tirzepatide, Elite combined) plus $100-off-first-order intro pricing ($112 first month on Core with code SUMMER100).
Score Breakdown
Pros
- ✓Baseline and ongoing metabolic labs (CMP, lipids, TSH, HbA1c) at Quest every 6 months — rare for compounded GLP-1
- ✓Mandatory video visit with a US-licensed MD or NP before your first prescription — not a pure questionnaire model
- ✓Three tiers, including a combined semaglutide + tirzepatide Elite plan ($322/mo) for patients plateaued on one GLP-1
- ✓Uses LegitScript-certified 503A pharmacies (Tru Meds Rx, Strive Pharmacy, Pharmacy Hub)
- ✓Intro pricing via $100 off your first order (code SUMMER100): $112 Core, $180 Advanced, $222 Elite first month
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Not available in 10 states: AL, AR, GA, HI, LA, MS, MO, SC, TN, WV
- ✗Mandatory lab work adds 5–10 days to onboarding vs async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗Intro discount applies only to the first order — ongoing rates are $212–$322/mo on 12-month plans, or $249–$379/mo month-to-month
Gala
Verified partnerBest for: compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide
Gala (legal entity AI Coaching Inc., d/b/a Gala GLP-1) is a Delaware-incorporated telehealth platform offering compounded semaglutide and compounded tirzepatide on a yearly subscription, a lower-priced microdosing program, and brand-name Ozempic. The marketing site claims licensed providers in all 50 states with free shipping included. An oral Wegovy pill option is listed as 'coming soon.'
Score Breakdown
Pros
- ✓Compounded semaglutide and tirzepatide at $179/mo with all doses included on the yearly plan
- ✓Lower microdosing tirzepatide tier at $149/mo for a sub-therapeutic starting protocol
- ✓Brand-name Ozempic available alongside compounded options
- ✓Claims licensed providers in all 50 states with free shipping included
- ✓24/7 support, provider visit included, cancel anytime
- ✓LegitScript verified
Cons
- ✗$179/mo requires a yearly subscription — the standalone monthly price isn't published
- ✗Brand-name Ozempic at $1,299/mo is higher than peers (e.g., Found at $1,100/mo)
- ✗Pharmacy partners not named — only a "network of pharmacies" reference
- ✗Wegovy oral pill listed as "coming soon," not yet available
- ✗Per-state availability isn't listed; the all-50-states claim is gated behind intake
bmiMD
Verified partnerBest for: mainstream telehealth GLP-1 access
Medical weight loss clinic offering GLP-1 prescriptions through telehealth.
Score Breakdown
Pros
- ✓Both semaglutide and tirzepatide available
Cons
- ✗Pricing not publicly disclosed
RxSpan MD
Verified partnerBest for: shoppers wanting physician-led, pharmacy-transparent compounded GLP-1 with brand-name options
RxSpan MD is a physician-led telehealth practice founded by Dr. John Diaz, a board-certified plastic surgeon, offering compounded GLP-1 weight loss — semaglutide and tirzepatide from $249/mo, as injections or oral capsules — plus brand-name Wegovy, Zepbound and Ozempic. It's unusually transparent: it names its 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma) and medical group, ships free, and includes unlimited 24/7 support. Available in all 50 states.
Score Breakdown
Pros
- ✓Physician-led — founded by Dr. John Diaz, a board-certified plastic surgeon with 20+ years' experience
- ✓Compounded semaglutide and tirzepatide from $249/mo (injection or oral capsules), plus brand-name Wegovy, Zepbound and Ozempic
- ✓Names its 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma) and medical group
- ✓LegitScript-certified (#50405601); free expedited shipping and unlimited 24/7 support included
- ✓Available in all 50 states via a 2-minute assessment
Cons
- ✗Compounded pricing ($249 semaglutide / $329 tirzepatide) sits mid-to-high versus the cheapest telehealth options
- ✗Brand-name GLP-1 is priced steeply (Wegovy $1,349, Ozempic $1,299, Zepbound $1,069)
- ✗Multi-vertical practice (also hair, sexual health, longevity), not weight-loss-only
- ✗Legal entity name isn't published on the site
How to choose a semaglutide provider
Semaglutide (Wegovy, Ozempic, and compounded versions) is the most-prescribed GLP-1. The molecule is the same everywhere — what differs is the pharmacy, the clinical care, and the true monthly cost.
What to look for
- Brand vs. compounded. Decide whether you want FDA-approved brand-name Wegovy/Ozempic (higher cost, standardized dosing) or lower-cost compounded semaglutide from a licensed pharmacy. Providers that offer both give you room to switch.
- Dose-titration support. Semaglutide is titrated over months. Favor providers whose clinicians adjust the schedule and slow it down if side effects hit, rather than a fixed ladder with no flexibility.
- All-in monthly price. Compare the ongoing price after any intro month, plus any membership fee — not just the headline number.
Red flags to avoid
- No named pharmacy or LegitScript listing. A legitimate compounded-GLP-1 provider names its 503A/503B pharmacy partner and carries LegitScript certification. If neither is disclosed, you can't verify what you're injecting.
- Async-only, no real clinician review. A prescriber should review your intake and be reachable for dose questions. Instant approval with no way to reach a clinician is a safety gap.
- Teaser pricing that hides the real cost. A low 'first month' price that jumps at higher doses, or a membership fee stacked on top of the medication, can double the true monthly total. Confirm the ongoing, all-in price before you pay.
- Weight-loss claims for B12, MIC, or HCG shots. Only GLP-1 injections have trial evidence for weight loss. A clinic selling B12, lipotropic, or HCG shots as a weight-loss treatment is a red flag.
Every provider ranked above is scored against these criteria across our six-dimension methodology, and prices are re-verified against each provider’s live site.
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support. Compounded GLP-1s from licensed 503A and 503B pharmacies are legal under federal compounding law[2], with additional tolerances historically allowed while semaglutide and tirzepatide were on the FDA Drug Shortage List[3].
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Wegovy · Drugs and brands
- Ozempic · Drugs and brands
- Rybelsus · Drugs and brands
- Semaglutide · Drugs and brands
- GLP-1 receptor · Mechanism
- STEP-1 · Major trials
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.